TherapeuticsMD (TXMD) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 Product Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
February 20, 2020 6:57 AM EST- 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Companys Financial Guidance -
- Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance -
- Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive -
- Company Expects Full-Year 2020 Net Product Revenue of $90 Million to $110 Million -
- Conference Call Scheduled for 8:30 a.m. ET Today -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company,... More
